Opioid Overdose Antidote Gets A Nod From NY AG

Opioid Overdose Antidote Gets A Nod From NY AG

Introduction

On Thursday, New York's attorney general Letitia James announced a deal stating more companies will be able to make an easy-to-use version of opioid overdose antidote.

As per the agreement by the attorney general’s office, Adapt Pharma, which was acquired by Rockville, Maryland-based Emergent BioSolutions in 2018, had the sole rights to sell the drug nalmefene using Aptar Pharma's nasal spray technology. Following the agreement, Emergent will no longer hold a contract that allowed it to be the only company to develop a nasal spray using nalmefene, which is still in the making and not in the market.

The agreement will not affect already in use Narcan, a spray version of the drug naloxone now sold by Emergent, as the agreement is not subject to spray technology. Narcan is popular among police, firefighters, and others who use it on people affected by overdose.

The easy-to-use version antidote would still require Food and Drug Administration approval before the product goes into the market.

Opioids are on the market for ages and have been used basically for pain relief for post-surgical pain, cancer-related pain, chronic or persistent pain. Opioids when used in proper dosage and along with a combination of other pain treatments, work in relieving pain successfully, unless there is a misuse or abuse of the drug.

Companies manufacturing opioids convinced the medical community that these medications were not addictive and were purely beneficial. This belief raised the number of prescriptions and sales unwarrantedly, resulting in a mass misuse of these drugs, to the extent that this was identified by the U.S. Food and Drug Administration (FDA) as a public issue and named it an opioid crisis